Critically Ill Patients With COVID-19 Disease Benefited from IL-7 Treatment

The findings of a study published by JAMA suggest that IL-7 can be safely administered to critically ill patients with COVID-19 without exacerbating inflammation or pulmonary injury. IL-7 was associated with a restored lymphocyte count, with the IL-7 group having levels more than 2-fold greater than the control group.

“IL-7 was associated with lymphocytes returning to a reference level, appearing to reverse a pathologic hallmark of COVID-19," said these researchers.